S-1/A: Veri Medtech Files S-1/A for Public Offering Amid Losses

Veri Medtech Holdings, Inc. filed an S-1/A registration statement for a firm commitment public offering of common stock, seeking capital while reporting significant net losses and a going concern doubt.

Summary

• Veri Medtech Holdings, Inc. (VERI) is pursuing a firm commitment public offering of an unspecified number of common shares, with an estimated public offering price between $[] to $[] per share.
• The company intends to apply for listing its Common Stock on The NYSE American Market under the symbol VRHI, currently quoted on the OTCID Market at $1.60 per share as of December 5, 2025.
• Veri Medtech operates as a holding company with wholly-owned subsidiaries: Veriheal Inc., DosePop Inc. (f/k/a Verinew), Alternative Medical Clinic LLC, and newly formed Sky Clinics LLC.
• Veriheal, the primary operating entity, provides concierge services for medical marijuana prescription cards and education, having processed over 400,000 patient approvals and generated over $100 million in revenue since inception to December 31, 2025.
• DosePop is a direct-to-consumer healthcare technology platform targeting Millennials and Gen Z for wellness, mental health, and lifestyle-enhancing medications, with a soft launch revenue of ~$24,000 and ~$5,000 in recurring monthly revenue.
• The company reported a net loss of approximately ($409,000) for the year ended December 31, 2024, a significant decline from a net income of $3,530,000 in 2023.
• For the nine months ended September 30, 2025, a net loss of approximately ($1,305,000) was reported, compared to a net loss of ($274,000) for the same period in 2024.
• Revenues decreased by approximately 25% to $16.7 million in 2024 from $22.2 million in 2023, primarily due to regulatory changes in states like Florida, Arizona, and Colorado mandating in-person consultations for medical marijuana certifications.
• Revenues for the nine months ended September 30, 2025, were approximately $8.7 million, a 36% decrease from $13.4 million in the same period of 2024.
• The company had a stockholders deficit, accumulated deficit, and working capital deficit of approximately $1,958,000, $3,826,000, and $2,024,000, respectively, at September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Management estimates a minimum funding of approximately $3,000,000 is required to remain in business for at least the next 12 months from the date of the report.
• The net proceeds from the offering are estimated to be approximately $[] million, assuming a public offering price of $[] per share, and will be used for organic and acquisitive growth, and working capital.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with low sentiment due to significant financial losses, declining revenues driven by regulatory headwinds, and a stated 'going concern' risk, despite strategic growth initiatives and market positioning.

Positives

• Veriheal, a subsidiary, has a strong track record, processing over 400,000 medical cannabis patient approvals and generating over $100 million in revenue since inception to December 31, 2025.
• Veriheal holds a leading market position with 5.3% of the U.S. cannabis card approvals and the largest state-by-state coverage for telemedicine and in-person consultations.
• The company has a diversified healthcare technology strategy with the introduction of DosePop, targeting the broader D2C health and wellness market (weight loss, mental health, dermatology, anti-aging, sexual health).
• DosePop aims to leverage Veriheal's existing patient pipeline for lower customer acquisition costs and higher patient lifetime value through a 'Infinite Wellness Loop' strategy.
• The global medical cannabis market is projected to reach $40 billion by 2030, and the U.S. D2C healthcare technology industry is expected to exceed $180 billion by 2030, indicating significant market opportunities.
• The company has implemented cost-cutting measures, leading to decreases in professional, consulting, contractor fees, and general and administrative expenses in 2024 and 9M 2025.
• Gross margins remained strong at approximately 74% in 2024 and 76% for the nine months ended September 30, 2025.

Negatives

• The company reported a net loss of approximately ($409,000) for the year ended December 31, 2024, a significant decrease from a net income of $3,530,000 in 2023.
• A net loss of approximately ($1,305,000) was incurred for the nine months ended September 30, 2025, compared to a net loss of ($274,000) in the prior year period.
• Revenues declined by approximately 25% in 2024 to $16.7 million from $22.2 million in 2023, and by 36% for the nine months ended September 30, 2025, to $8.7 million from $13.4 million in 2024.
• The decline in revenues is primarily attributed to regulatory changes in key states (e.g., Florida, Arizona, Colorado) mandating in-person consultations for medical marijuana certifications, impacting the telemedicine-reliant business model.
• The company has a stockholders deficit, accumulated deficit, and working capital deficit of approximately $1,958,000, $3,826,000, and $2,024,000, respectively, at September 30, 2025, raising substantial doubt about its ability to continue as a going concern.
• Sales and marketing expenses increased by approximately $513,000 in 2024, despite declining revenues, indicating potentially inefficient customer acquisition.
• The company has a limited operating history and is in the initial commercialization stage, facing inherent risks of new business enterprises such as limited capital and uncertain markets.

Risks

• Limited operating history and evolving business make it difficult to evaluate current business and future prospects, and past success may not indicate future results.
• Failure to effectively manage rapid growth or improve systems and processes could adversely affect business, financial condition, and results of operations.
• Inability to attract new clients or broaden existing clients' use of solutions could materially and adversely affect the business.
• Failure to maintain, protect, and enhance the brand would hurt the ability to retain or expand the client base.
• Inaccurate prediction of long-term client subscription renewals or solution adoption rates could impact revenues.
• Performance issues, errors, or failure to integrate/license necessary third-party software, content, or services could cause delays, errors, increased expenses, and reduced sales.
• Inability to effectively integrate solutions with other client systems or performance issues with third-party systems could hinder effective operation.
• Intense competition from large, well-established healthcare providers with significant resources could lead to market share loss.
• Dependence on the healthcare technology, telemedicine, and alternative medicine industries means any downturn, consolidation, or decrease in healthcare spending could materially affect the business.
• A breach or compromise of security measures could result in unauthorized access to personal information or system disruptions, impacting reputation and financials.
• Failure to comply with laws and regulations applicable to a telemedicine, alternative medicine healthcare technology service provider could lead to adverse effects, increased costs, and operational constraints.
• Privacy and data security concerns, data collection/transfer restrictions, and evolving laws could limit platform use and adoption.
• Quarterly and annual results of operations are likely to fluctuate due to various factors, making forecasting difficult.
• The sales cycle can be unpredictable, time-consuming, and costly.
• Intense competition for key employees may hinder the ability to attract and retain highly skilled personnel.
• Inability to protect intellectual property rights could reduce the value of products, services, and brand.
• Claims by others of intellectual property infringement could be costly to defend and limit operations.
• The healthcare technology market is immature and volatile, and if it does not develop as hoped, business growth will be harmed.
• Inability to expand the scope of services, including the number and quality of healthcare providers, and the number of individuals treated through the platform, could adversely affect the business.
• Inability to successfully market to new customers and retain existing customers, or restrictive healthcare laws, could harm the business.
• Heavy reliance on Facebook, Google, Amazon, and other social networks/search engines for customer acquisition means changes to advertising policies could materially adversely affect revenue.
• Inability to expand marketing infrastructure may prevent meeting forecasts.
• Revenue growth depends on consumers' willingness to adopt the product; failure to achieve and maintain market acceptance could result in revenue below expectations.
• The consolidated financial statements have been prepared on a going concern basis, raising substantial doubt about the ability to continue as a going concern.
• Broad discretion in the use of offering proceeds means investors will have no control over how funds are allocated.
• The market may not accept the products, and competing alternatives may have advantages.
• The company may incur losses in the foreseeable future and may be unable to sustain or increase profitability.
• Projections are based on assumptions with significant uncertainties, and actual financial conditions may differ materially.
• The successful implementation of the business plan is dependent upon key personnel, and the loss of executive officers or inability to attract/retain qualified personnel could harm the business.
• Business is subject to State Corporate Practice of Medicine and Fee Splitting Laws, and non-compliance could lead to adverse actions.
• Premature abandonment of products, services, or development stages due to commercial infeasibility could result in loss of expended funds.
• The business revenue generation model is unproven and could fail.
• Inability to maintain relationships with customers and counterparties could have a material adverse effect.
• Damage to the company's reputation could harm its business.
• Inability to adapt to changing market conditions could adversely affect the business.
• States adopting laws legalizing recreational cannabis could diminish demand for medicinal cannabis.
• Government regulation of healthcare creates risks and challenges for compliance and business strategies.
• Inaccurate or incomplete information provided to healthcare providers, customers, and partners could harm the business and lead to liability claims.
• Use, disclosure, and processing of personally identifiable information is subject to federal, state, and foreign privacy and security regulations, and failure to comply could result in significant liability or reputational harm.
• Public scrutiny of internet privacy and security issues may result in increased regulation and different industry standards, deterring service provision.
• Cyber security risks and failure to maintain data integrity could expose the company to data loss, litigation, and liability.
• Disruption of service at Amazon Web Services or other third-party service providers could interrupt platform access.
• Dependence on third-party medical groups, payment processors, and suppliers for critical functions increases vulnerability.
• Cannabis companies face significant scrutiny from payment processors due to federal illegality, complicating banking relationships and payment options.
• Pricing decisions may adversely affect the ability to attract new customers and healthcare providers.
• Increased costs and demands upon management due to complying with public company laws and regulations could adversely affect the business.
• Certain U.S. state tax authorities may assert a state nexus and seek to impose state and local income and sales taxes.
• As a holding company, dependence on operating subsidiaries for cash to fund operations and expenses.
• Charter documents and Delaware law could make it more difficult for a third party to acquire the company.
• Elimination of monetary liability against directors, officers, and employees under Delaware law and indemnification rights may result in substantial expenditures and discourage lawsuits.
• No current intention to pay dividends; return on investment depends solely on stock price appreciation.
• Potential future issuance of additional shares of common stock, exercise of warrants, and incentive stock grants may dilute ownership interest and negatively impact stock price.
• Market price of securities is likely to be highly volatile and subject to wide fluctuations.
• If securities or industry analysts cease publishing research or publish inaccurate/unfavorable reports, stock price and trading volume could decline.
• A substantial portion of total issued and outstanding shares may be sold into the market at any time, causing significant price drops.
• If the NYSE American listing application is not approved, the offering will not be consummated, making it difficult for stockholders to dispose of common stock.
• As an emerging growth company, reduced reporting requirements may make common stock less attractive to some investors, leading to a less active trading market and more volatile prices.

Future Outlook

The company plans to use the net proceeds from this offering to fund organic and acquisitive growth, and other business purposes. It aims to expand Veriheal's operations into new states and international markets (e.g., Germany, France, Canada) and unlock new revenue streams through data monetization. DosePop is strategically positioned to lead the direct-to-consumer healthcare technology industry, with plans for rapid expansion into weight loss, ADHD, dermatology, anti-aging, and sexual health treatments, including potential strategic acquisitions in these verticals. Management believes existing available capital resources will be sufficient for 3 to 6 months, but requires a minimum of $3,000,000 to operate for the next 12 months.

Management Comments

• "The decline in revenues was primarily driven by regulatory changes affecting telemedicine services. The state of Florida, a top 10 state in our market, revised its requirements, mandating in-person consultations for medical marijuana certifications instead of allowing online telemedicine. Similar restrictions were implemented in states such as Arizona and Colorado."
• "Management remains focused on improving cash flow efficiency and exploring opportunities to optimize working capital through better expense controls."
• "Based on current forecasts and available cash as of September 30, 2025, the Company may require additional capital to fully support its planned growth initiatives and capital expenditures over the next twelve months."
• "The Company believes that our existing available capital resources which includes available cash and financing resources, will be sufficient to fund our planned operations between 3 to 6 months from the date of this report."
• "Management has determined that a minimum funding of approximately $3,000,000 is required to remain in business for at least the next 12 months from the date of this report."
• "Veri MedTech was built on the foundation of solving real-world healthcare access challenges. The Company began with its first subsidiary, Veriheal, which quickly became the largest medical cannabis healthcare technology platform in the U.S., providing seamless doctor-patient connectivity, patient education, and digital prescription approvals."
• "With this track record of success in the alternative medicine space, the Company is now expanding its business model into broader healthcare technology through DosePop—a next-generation, direct-to-consumer healthcare technology platform designed specifically for Millennials and Gen Z."
• "This strategic synergy—referred to as the Infinite Wellness Loop—allows Veri MedTech to cross-sell, retain, and maximize patient lifetime value in a way that no other healthcare technology provider currently does."
• "Veri MedTech is poised to become the dominant force in the next generation of digital healthcare. the Company is redefining patient access, removing barriers to treatment, and creating an ecosystem where healthcare is convenient, personalized, and stigma-free."

Industry Context

StockSavvy.ai notes that Veri Medtech operates at the intersection of the rapidly growing medical cannabis and direct-to-consumer (D2C) healthcare technology markets. While the medical cannabis sector faces evolving regulatory challenges, the D2C health market, particularly in areas like weight loss and mental health, presents substantial growth opportunities. The company's 'Infinite Wellness Loop' strategy, aiming to cross-sell between its Veriheal (medical cannabis) and DosePop (D2C wellness) platforms, is a strategic attempt to leverage its existing patient base and reduce customer acquisition costs, a common challenge in competitive digital health sectors. However, the significant revenue decline due to regulatory shifts in medical cannabis highlights the inherent volatility and regulatory risk in this niche, contrasting with the broader D2C market's potential.

Comparison to Industry Standards

• Veriheal is positioned as the largest volume issuer of cannabis cards (5.3% US market share) and maintains the largest coverage area in the US among its competitors, including Leafwell and NuggMD, which are described as smaller-scale healthcare technology platforms with limited state coverage.
• The company differentiates itself from competitors by offering both online and in-person doctor consultations, unlike key competitors that offer online consultations only.
• DosePop aims to differentiate from legacy healthcare technology companies like HIMS, Ro, and Teladoc by focusing on Millennial and Gen Z-focused branding, AI-driven patient engagement, and a subscription-based model to maximize lifetime patient value, rather than transactional interactions.
• DosePop's integration with Veriheal's existing patient pipeline (400,000+ patients) is noted as a significant advantage for rapid expansion into new healthcare verticals, potentially leading to significantly lower customer acquisition costs compared to traditional healthcare technology companies reliant on high digital advertising expenditures.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently subject to any material legal proceedings.
• Contingent liabilities arising from potential litigation are assessed by management based on individual analysis and legal consultants' opinions; no provisions recorded for 2024 and 2023.

Related Party Transactions

• As of September 30, 2025, $112,779 was payable to G&A Real Estate Investment Group, LLC, an affiliated company owned by the principal stockholders, primarily for unpaid rent. This amount is unsecured and non-interest bearing.
• In October 2023, Veriheal entered into a ten-year lease agreement with G&A Real Estate Investment Group, LLC for a monthly rent of $15,000. This lease was amended on July 1, 2025, shortening the term to October 2025, with month-to-month renewals thereafter.
• During the nine months ended September 30, 2025, the company's officers advanced an aggregate of $178,943 for working capital purposes. These loan advances bear no interest and are payable on demand.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from the public offering, exercise of underwriters' warrants, and future equity incentive plan grants. The 'going concern' doubt and recent losses pose a risk to investment value. However, the IPO aims to provide capital for growth.
• **Employees:** The 2025 Equity Incentive Plan provides opportunities for equity ownership, potentially enhancing motivation and retention. However, salary adjustments for executive officers (decreases) and a decreased number of employees suggest cost-cutting pressures.
• **Customers:** Regulatory changes requiring in-person consultations in some states have negatively impacted the telemedicine-reliant business model, potentially affecting customer access and convenience in those regions. Expansion into broader D2C health aims to serve new customer segments.
• **Creditors:** The substantial working capital deficit and 'going concern' doubt indicate increased risk for creditors, although management states it continues to meet obligations and is focused on improving cash flow.
• **Management:** Executive officers' compensation includes stock awards and potential earn-out shares tied to stock price performance post-IPO, aligning their interests with shareholder value. However, they face the challenge of navigating regulatory changes and achieving profitability.

Next Steps

• Consummate the public offering of common stock.
• Apply to list common stock on The NYSE American Market under the symbol VRHI.
• Continue to implement business plan, generate sufficient revenues, and raise additional capital resources as needed to address going concern doubt.
• Expand Veriheal's operations into new states and international markets (e.g., Germany, France, Canada).
• Unlock new revenue streams through data monetization from Veriheal's patient dataset.
• Broaden Veriheal's service offerings to include mental health therapy, sleep coaching, holistic wellness coaching, and lifestyle optimization programs.
• DosePop to continue expansion into weight loss, ADHD, dermatology, anti-aging, and sexual health treatments.
• Actively pursue strategic acquisitions for DosePop in complementary healthcare technology verticals (e.g., ADHD platform, naltrexone/alcohol recovery service, AI-powered diagnostics, prescription fulfillment center).
• The 2025 Equity Incentive Plan has been approved, reserving 50,000,000 shares of Common Stock for future awards.

Key Dates

Recommendation

The company faces substantial financial challenges, including significant net losses in 2024 and 9M 2025, and a material decline in revenue, primarily due to adverse regulatory changes impacting its core medical cannabis telemedicine business. The 'going concern' qualification from auditors highlights severe liquidity and capital resource issues, with management explicitly stating a need for $3 million in additional capital within 12 months. While the public offering aims to address this, the inherent risks of an unproven business model in a volatile, heavily regulated industry, coupled with intense competition and potential dilution, suggest a high-risk investment profile. Seasoned investors would likely view the current financial instability and operational headwinds as strong indicators to sell or avoid investment until a clear path to sustained profitability and financial stability is demonstrated.

Keywords

Healthcare Technology, Medical Cannabis, Telemedicine, D2C Healthcare, SEC Filing, S-1/A, Public Offering, Veriheal, DosePop, VRHI, Going Concern, Regulatory Risk, Cannabis Industry, Digital Health, IPO